CCU Translational Immunology Image Video

"Cure for cancer finally succeeded!" We have all been waiting for this headline for decades. Unfortunately, we also know that it is not that simple. Developing new therapies in research laboratories and then applying them in the clinic usually takes several years, if not decades. Closing precisely this gap and bringing innovative therapeutic approaches into the clinic as quickly as possible is the vision of the Clinical Cooperation Unit Translational Immunology at the University Hospital Tübingen. Under the direction of Prof. Helmut Salih, immunotherapies are developed here, especially for cancer patients, in order to then quickly test them in clinical trials. The current example of the corona vaccine "CoVac-1" developed at the KKE under the direction of Prof. Juliane Walz shows that this vision is even becoming reality. This is intended in particular for cancer patients with a very weak immune system and is already well advanced in clinical trials.

But see for yourself in the video and learn what distinguishes the KKE Translational Immunology and how closely it is linked to our iFIT Cluster of Excellence: https://www.youtube.com/watch?v=ZOFni2dQZC0